Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

PAN-TB COLLABORATION ANNOUNCES THE START OF A PHASE 2 CLINICAL TRIAL TO EVALUATE TWO NOVEL TUBERCULOSIS TREATMENT REGIMENS

PRNewswire | August 10, 2023

news image

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the start of a phase 2b/c clinical trial, sponsored by the Bill & Melinda Gates Medical Research Institute (Gates MRI). The trial will evaluate whether novel regimens that combine registered products and new chemical entities have the potential to effectively treat drug-sensitive TB (DS-TB) and inform the development of a "pan-TB" regimen capable of treating all forms of active pu...

Read More

ALZECURE PHARMA PROVIDES A SCIENTIFIC UPDATE ON ALZHEIMER'S DISEASE AND THE ALZSTATIN PROJECT PLATFORM

AlzeCure Pharma | September 28, 2020

news image

CEO Martin Jönsson and CSO Johan Sandin will, among other things, present the pharmaceutical platform Alzstatin and the research behind it. Within the Alzstatin platform, AlzeCure develops disease-modifying and preventive drugs for Alzheimer's disease that focus on reducing the production of toxic amyloid beta (Aβ) in the brain. Henrik Zetterberg, chief physician and professor at the Department of Neuroscience and Physiology at Sahlgrenska Academy and professor at University Colleg...

Read More

PHARMACY MARKET, PHARMA TECH

MERCK & XTALPI COLLABORATION OPTIMIZES DRUG FORMULATIONS WITH AI-POWERED TECHNIQUES

prnewswire | April 18, 2023

news image

Science and technology company Merck and XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, have jointly published a study that highlights the benefits of combining computational workflows with wet lab experiments to advance drug development. Traditional methods like milling and micronization, used to address undesirable crystal morphologies, can be disruptive and costly. In contrast, molecular dynamics simulations...

Read More

Pharmacy Market

GINKGO BIOWORKS ADVANCES COLLABORATION WITH NOVO NORDISK ON EXPRESSION SYSTEMS FOR PHARMACEUTICAL PRODUCTS

PRNewswire | July 13, 2023

news image

Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity, today announced the completion of the pilot phase of their previously announced partnership with Novo Nordisk, a leading global healthcare company, to develop expression systems for pharmaceutical products. With the pilot phase completed and the first milestone achieved, the two companies will now move into the development phase to work towards making a more effective production process. Achievemen...

Read More
news image

Pharmacy Market

PAN-TB COLLABORATION ANNOUNCES THE START OF A PHASE 2 CLINICAL TRIAL TO EVALUATE TWO NOVEL TUBERCULOSIS TREATMENT REGIMENS

PRNewswire | August 10, 2023

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the start of a phase 2b/c clinical trial, sponsored by the Bill & Melinda Gates Medical Research Institute (Gates MRI). The trial will evaluate whether novel regimens that combine registered products and new chemical entities have the potential to effectively treat drug-sensitive TB (DS-TB) and inform the development of a "pan-TB" regimen capable of treating all forms of active pu...

Read More
news image

ALZECURE PHARMA PROVIDES A SCIENTIFIC UPDATE ON ALZHEIMER'S DISEASE AND THE ALZSTATIN PROJECT PLATFORM

AlzeCure Pharma | September 28, 2020

CEO Martin Jönsson and CSO Johan Sandin will, among other things, present the pharmaceutical platform Alzstatin and the research behind it. Within the Alzstatin platform, AlzeCure develops disease-modifying and preventive drugs for Alzheimer's disease that focus on reducing the production of toxic amyloid beta (Aβ) in the brain. Henrik Zetterberg, chief physician and professor at the Department of Neuroscience and Physiology at Sahlgrenska Academy and professor at University Colleg...

Read More
news image

PHARMACY MARKET, PHARMA TECH

MERCK & XTALPI COLLABORATION OPTIMIZES DRUG FORMULATIONS WITH AI-POWERED TECHNIQUES

prnewswire | April 18, 2023

Science and technology company Merck and XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, have jointly published a study that highlights the benefits of combining computational workflows with wet lab experiments to advance drug development. Traditional methods like milling and micronization, used to address undesirable crystal morphologies, can be disruptive and costly. In contrast, molecular dynamics simulations...

Read More
news image

Pharmacy Market

GINKGO BIOWORKS ADVANCES COLLABORATION WITH NOVO NORDISK ON EXPRESSION SYSTEMS FOR PHARMACEUTICAL PRODUCTS

PRNewswire | July 13, 2023

Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity, today announced the completion of the pilot phase of their previously announced partnership with Novo Nordisk, a leading global healthcare company, to develop expression systems for pharmaceutical products. With the pilot phase completed and the first milestone achieved, the two companies will now move into the development phase to work towards making a more effective production process. Achievemen...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us